Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 12/20 | 0.59 |
| ▸ | PIK3CG | P48736 | 11/20 | 0.54 |
| ▸ | PIK3CB | P42338 | 10/20 | 0.54 |
| ▸ | PIK3CA | P42336 | 7/20 | 0.54 |
| ▸ | PIK3R1 | P27986 | 4/20 | 0.54 |
| ▸ | PIK3R2 | O00459 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16677220 | 0.94 | PIK3CB (0.61) | PIK3CDPIK3CGPIK3CBPIK3CAPIK3R1 | |
| SCHEMBL16677399 | 0.94 | PIK3CB (0.61) | PIK3CDPIK3CGPIK3CBPIK3CAPIK3R1 | |
| SCHEMBL16677752 | 0.94 | PIK3CB (0.61) | PIK3CDPIK3CGPIK3CBPIK3CAPIK3R1 | |
| SCHEMBL367317 | 0.91 | PIK3CD (0.60) | PIK3CDPIK3CGPIK3CBPIK3CAPIK3R1 | |
| SCHEMBL356115 | 0.91 | PIK3CD (0.60) | PIK3CDPIK3CGPIK3CBPIK3CAPIK3R1 | |
| SCHEMBL13112856 | 0.91 | PIK3CD (0.61) | PIK3CDPIK3CGPIK3CBPIK3CAPIK3R1 | |
| SCHEMBL733879 | 0.91 | PIK3CD (0.63) | PIK3CDPIK3CGPIK3CBPIK3CAPIK3R1 | |
| SCHEMBL18031947 | 0.90 | PIK3CD (0.58) | PIK3CDPIK3CGPIK3CBPIK3CAPIK3R1 | |
| SCHEMBL18031899 | 0.90 | PIK3CD (0.58) | PIK3CDPIK3CGPIK3CBPIK3CAPIK3R1 | |
| SCHEMBL18031914 | 0.90 | PIK3CD (0.58) | PIK3CDPIK3CGPIK3CBPIK3CAPIK3R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1885356-A2 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS FOR INHIBITING LEUKOCYTE ACCUMULATION | ICOS CORPORATION (US) | 2008-02-13 | — | — | EP | claimed |
| EP-1755609-A1 | METHODS FOR TREATING AND/OR PREVENTING ABERRANT PROLIFERATION OF HEMATOPOIETIC CELLS | ICOS CORPORATION (US) | 2007-02-28 | — | — | EP | claimed |
| EP-1750715-A1 | METHODS FOR TREATING MAST CELL DISORDERS | ICOS CORPORATION (US) | 2007-02-14 | — | — | EP | claimed |
| EP-1750714-A1 | PHOSPHOINOSITIDE 3-KINASE DELTA SELECTIVE INHIBITORS FOR INHIBITING ANGIOGENESIS | VANDERBILT UNIVERSITY (US) | 2007-02-14 | — | — | EP | claimed |
| WO-2006089106-A2 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS FOR INHIBITING LEUKOCYTE ACCUMULATION | ICOS CORPORATION (US) | 2006-08-24 | — | — | WO | claimed |
| US-20060106038-A1 | Methods for treating and/or preventing aberrant proliferation of hematopoietic cells | ICOS CORPORATION (US) | 2006-05-18 | — | — | US | claimed |
| US-20060079538-A1 | Methods for inhibiting angiogenesis | VANDERBILT UNIVERSITY | 2006-04-13 | — | — | US | claimed |
| WO-2005120511-A1 | METHODS FOR TREATING MAST CELL DISORDERS | ICOS CORPORATION (US) | 2005-12-22 | — | — | WO | claimed |
| WO-2005117889-A1 | METHODS FOR TREATING AND/OR PREVENTING ABERRANT PROLIFERATION OF HEMATOPOIETIC | ICOS CORPORATION (US) | 2005-12-15 | — | — | WO | claimed |
| WO-2005112935-A1 | PHOSPHOINOSITIDE 3-KINASE DELTA SELECTIVE INHIBITORS FOR INHIBITING ANGIOGENESIS | VANDERBILT UNIVERSITY (US) | 2005-12-01 | — | — | WO | claimed |
| US-20050054614-A1 | Methods of inhibiting leukocyte accumulation | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-03-10 | — | — | US | claimed |
| US-20050043239-A1 | Methods of inhibiting immune responses stimulated by an endogenous factor | ICOS CORPORATION | 2005-02-24 | — | — | US | claimed |
| WO-2005016349-A1 | METHODS OF INHIBITING LEUKOCYTE ACCUMULATION | ICOS CORPORATION (US) | 2005-02-24 | — | — | WO | claimed |
| WO-2005016348-A1 | METHOD OF INHIBITING IMMUNE RESPONSES STIMULATED BY AN ENDOGENOUS FACTOR | ICOS CORPORATION (US) | 2005-02-24 | — | — | WO | claimed |
| EP-2018385-B1 | THIAZOLYL-DIHYDROQUINAZOLINES | BOEHRINGER INGELHEIM INT (DE) | 2013-05-15 | — | — | EP | disclosed |
| US-8354418-B2 | Thiazolyl-dihydro-quinazolines | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-01-15 | — | — | US | disclosed |
| US-8334378-B2 | Thiazolyl-dihydro-quinazoline compounds and processes for preparing same | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-12-18 | — | — | US | disclosed |
| US-20050043239-A1 | Methods of inhibiting immune responses stimulated by an endogenous factor | ICOS CORPORATION | 2005-02-24 | — | — | US | disclosed |
| WO-2005016348-A1 | METHOD OF INHIBITING IMMUNE RESPONSES STIMULATED BY AN ENDOGENOUS FACTOR | ICOS CORPORATION (US) | 2005-02-24 | — | — | WO | disclosed |
| WO-2005016349-A1 | METHODS OF INHIBITING LEUKOCYTE ACCUMULATION | ICOS CORPORATION (US) | 2005-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054614-A1 | Methods of inhibiting leukocyte accumulation | PI4KB, PIK3CD, PIK3CA | PIK3CD 2/4885PIK3CG 7/4885PIK3CB 4/4885 |
| US-20060079538-A1 | Methods for inhibiting angiogenesis | FLT4, KDR, PDGFRB | PIK3CD 6/4885PIK3CG 13/4885PIK3CB 14/4885 |
| US-20050043239-A1 | Methods of inhibiting immune responses stimulated by an endogenous factor | PI4KB, PI4KA, PIK3CD | PIK3CD 3/4885PIK3CG 10/4885PIK3CB 6/4885 |
| US-20060106038-A1 | Methods for treating and/or preventing aberrant proliferation of hematopoietic cells | MCL1, NFATC1, MKI67 | PIK3CD 25/4885PIK3CG 57/4885PIK3CB 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.